PoET WNV – now available

A new level of efficiency for WNV screening


Frankfurt/Main – GFE today announced the launch of its PoET WNV PCR kit. PoET WNV is a CE-IVD marked test, based on real-time PCR technology, for the detection of West Nile virus RNA in human plasma samples. PoET WNV is approved for mini-pool and individual donation testing and can be used for screening or confirmation. PoET WNV is designed as a dual target assay and features industry leading sensitivity.

In the last years, West Nile virus infections have been an increasing concern for blood safety in European countries. As approximately 80% of infected people are asymptomatic, there is a comparatively high risk of transfusion transmitted WNV. The screening of donor blood is therefore critical in preventing transmissions of West Nile virus.

“With its 95% LoD of 1,9 IU/mL, our PoET WNV test shows very high sensitivity. Used on our fully automated PoET Instrument, the test enables WNV screening with mini-pools containing 48 donations and still comply with the sensitivity requirements set forth by the Paul Ehrlich Institute in 2022. With our unique testing efficiency, we do not only provide a simple method to test large numbers of donations, but it’s very cost-efficient, too.” said Dr Holger Fey, Programme Manager PoET System at GFE.

This CE approval, combined with its continual expansion of the PoET blood screening portfolio, strengthens GFE’s mission to be a leading provider of fully automated integrated solutions for blood transfusion centres and laboratories.

About GFE:

GFE, “Company for research, development and distribution of diagnostics for the blood donation field”, founded in 2005, develops and distributes diagnostic applications and automation solutions for blood donation services. Shareholders of GFE are the German Red Cross Blood centres West and NSTOB as well as the Blood centre of the Bavarian Red Cross.

The detection methods are based on Nucleic Acids Amplification Technology (NAT) and are CE-IVD marked. GFE’s kits are used on the fully automated PoET Instrument.

GFE’s line of reagents provides all necessary components for the NAT testing of blood donations for the detection of HCV, HBV, HIV-1, HIV-2, HAV, B19V, HEV and WNV.

PoET Instrument, PoET HCV, PoET HBV, PoET HIV, PoET HAV, PoET B19V, PoET HEV and PoET WNV are not available in all countries. Please contact GFE for details.

News & Events

Market Launch of PoET System – Pushing blood screening forward

Frankfurt/Main – GFE today unveiled its vision for the future…

GFE and LVL Technologies strengthen supply of COVID-19 antigen tests

Frankfurt am Main; Crailsheim, March  12, 2021. – GFE and…

The partner for your NAT blood screening needs.

  • We provide high-end solutions for the blood screening process.
  • We analyse and customise NAT screening workflows.
  • We enable our customers to streamline their processes.
  • We support our customers to achieve regulatory compliance.
© Copyright - GFE